155 related articles for article (PubMed ID: 29608150)
1. Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity.
Sheehan K; Sheth S; Mukherjea D; Rybak LP; Ramkumar V
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29608150
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies.
Tang Q; Wang X; Jin H; Mi Y; Liu L; Dong M; Chen Y; Zou Z
Eur J Pharm Biopharm; 2021 Jun; 163():60-71. PubMed ID: 33775853
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent cochlear and vestibular toxicity of trans-tympanic cisplatin in the rat.
Callejo A; Durochat A; Bressieux S; Saleur A; Chabbert C; Domènech Juan I; Llorens J; Gaboyard-Niay S
Neurotoxicology; 2017 May; 60():1-9. PubMed ID: 28223157
[TBL] [Abstract][Full Text] [Related]
4. Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat.
Mukherjea D; Jajoo S; Kaur T; Sheehan KE; Ramkumar V; Rybak LP
Antioxid Redox Signal; 2010 Sep; 13(5):589-98. PubMed ID: 20214492
[TBL] [Abstract][Full Text] [Related]
5. Aminoglycoside- and Cisplatin-Induced Ototoxicity: Mechanisms and Otoprotective Strategies.
Kros CJ; Steyger PS
Cold Spring Harb Perspect Med; 2019 Nov; 9(11):. PubMed ID: 30559254
[TBL] [Abstract][Full Text] [Related]
6. Effect of intratympanic dexamethasone administration on cisplatin-induced ototoxicity in adult guinea pigs.
Shafik AG; Elkabarity RH; Thabet MT; Soliman NB; Kalleny NK
Auris Nasus Larynx; 2013 Feb; 40(1):51-60. PubMed ID: 22884636
[TBL] [Abstract][Full Text] [Related]
7. Local Drug Delivery for Prevention of Hearing Loss.
Rybak LP; Dhukhwa A; Mukherjea D; Ramkumar V
Front Cell Neurosci; 2019; 13():300. PubMed ID: 31338024
[TBL] [Abstract][Full Text] [Related]
8. Dexamethasone-loaded injectable silk-polyethylene glycol hydrogel alleviates cisplatin-induced ototoxicity.
Chen Y; Gu J; Liu J; Tong L; Shi F; Wang X; Wang X; Yu D; Wu H
Int J Nanomedicine; 2019; 14():4211-4227. PubMed ID: 31239676
[No Abstract] [Full Text] [Related]
9. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
Rolland V; Meyer F; Guitton MJ; Bussières R; Philippon D; Bairati I; Leclerc M; Côté M
J Otolaryngol Head Neck Surg; 2019 Jan; 48(1):4. PubMed ID: 30651130
[TBL] [Abstract][Full Text] [Related]
11. Targeted amelioration of cisplatin-induced ototoxicity in guinea pigs.
Mohan S; Smyth BJ; Namin A; Phillips G; Gratton MA
Otolaryngol Head Neck Surg; 2014 Nov; 151(5):836-9. PubMed ID: 25078416
[TBL] [Abstract][Full Text] [Related]
12. Ototoxicity: therapeutic opportunities.
Rybak LP; Whitworth CA
Drug Discov Today; 2005 Oct; 10(19):1313-21. PubMed ID: 16214676
[TBL] [Abstract][Full Text] [Related]
13. Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity.
Mukherjea D; Dhukhwa A; Sapra A; Bhandari P; Woolford K; Franke J; Ramkumar V; Rybak L
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):965-982. PubMed ID: 32757852
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of 1,2,3-triazole derivative KPR-A020 against cisplatin-induced ototoxicity in murine cochlear cultures.
Kim YR; Jung DJ; Oh SK; Lee T; Lee IK; Lee KY; Kim UK
Int J Pediatr Otorhinolaryngol; 2017 May; 96():59-64. PubMed ID: 28390615
[TBL] [Abstract][Full Text] [Related]
15. An Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect.
Bielefeld EC; Tanaka C; Chen GD; Coling D; Li M; Henderson D; Fetoni AR
Anticancer Drugs; 2013 Jan; 24(1):43-51. PubMed ID: 22828384
[TBL] [Abstract][Full Text] [Related]
16. Ginkgolide B protects against cisplatin-induced ototoxicity: enhancement of Akt-Nrf2-HO-1 signaling and reduction of NADPH oxidase.
Ma W; Hu J; Cheng Y; Wang J; Zhang X; Xu M
Cancer Chemother Pharmacol; 2015 May; 75(5):949-59. PubMed ID: 25749575
[TBL] [Abstract][Full Text] [Related]
17. Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss.
Hazlitt RA; Teitz T; Bonga JD; Fang J; Diao S; Iconaru L; Yang L; Goktug AN; Currier DG; Chen T; Rankovic Z; Min J; Zuo J
J Med Chem; 2018 Sep; 61(17):7700-7709. PubMed ID: 30091915
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients.
Viglietta V; Shi F; Hu QY; Ren Y; Keilty J; Wolff H; McCarthy R; Kropp J; Weber P; Soglia J
Invest New Drugs; 2020 Oct; 38(5):1463-1471. PubMed ID: 32157599
[TBL] [Abstract][Full Text] [Related]
19. Future opportunities in preventing cisplatin induced ototoxicity.
van den Berg JH; Beijnen JH; Balm AJ; Schellens JH
Cancer Treat Rev; 2006 Aug; 32(5):390-7. PubMed ID: 16781082
[TBL] [Abstract][Full Text] [Related]
20. Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy.
Riga MG; Chelis L; Kakolyris S; Papadopoulos S; Stathakidou S; Chamalidou E; Xenidis N; Amarantidis K; Dimopoulos P; Danielides V
Am J Clin Oncol; 2013 Feb; 36(1):1-6. PubMed ID: 22134515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
